EMERYVILLE, Calif.,
Aug. 5, 2021 /PRNewswire/
-- Zymergen Inc. (Nasdaq: ZY) today announced the appointments
of Lincoln Germain as Chief
Commercial Officer and Subodh
Deshmukh as Chief Development Officer.
Lincoln Germain, Chief
Commercial Officer, brings more than 25 years of experience in
senior positions at multinational materials, agrochemical and
consumer packaged goods corporations, most recently serving as Vice
President and Chief Commercial Officer at Honeywell International's
$3 billion Advanced Materials
business. As Zymergen's Chief Commercial Officer, Germain will lead
the rebuilding of the Company's commercial team, increasing the
robustness of our market and customer value discovery analysis, and
establishing a reliable sales pipeline qualification and
forecasting process.
Subodh Deshmukh, Chief
Development Officer, brings more than 20 years of experience
across all stages of product development, from research to
engineering and launch management at global scale. He most recently
served as Global Head of Product Development for Sandoz, the
$10 billion generics division of
Novartis, and previously held technical and executive leadership
positions with Sun Pharma, Pfizer and Bristol-Myers Squibb. As
Chief Development Officer, Deshmukh will oversee Zymergen's product
development process to ensure the robustness of the Company's
pipeline.
"We are pleased to welcome Lincoln and Subodh to the Zymergen
team as we continue enhancing our leadership team and position
Zymergen as a stronger company with a disciplined plan for growth
and value creation," said Jay
Flatley, Acting CEO and Chairman of the Board. "Both Lincoln
and Subodh are seasoned executives, and their significant
experience and expertise will be invaluable as we move forward.
Alongside Aindrea Campbell, who was
appointed Chief Manufacturing Officer in May, these appointments
will reinforce our strong focus on operations and advance our goal
of developing and delivering breakthrough products to the
market."
Germain commented, "Zymergen has immense potential to solve the
world's biggest problems through its unique integration of
genomics, machine learning and automation. I look forward to
working with the rest of the team to build a commercial
organization that understands its customers and end users, so that
we can consistently deliver the innovative products and solutions
they need to create substantial value."
"Like my new colleagues at Zymergen, I am passionate about
pushing scientific boundaries and fundamentally changing how
materials are made and what they are made of," Deshmukh added. "I'm
honored to work with the innovative team at Zymergen to design and
manufacture powerful products based on nature's own inventions that
meet market needs."
About Zymergen
Zymergen is a biofacturing company using biology to reimagine
the world. Zymergen partners with nature to design, develop and
manufacture bio-based breakthrough products that deliver value to
customers in a broad range of industries. A unique combination of
biology, chemistry, software and automation enables the company to
design and create new materials.
Forward Looking Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended. Such forward-looking statements are based on the
Company's beliefs and assumptions and on information currently
available to it on the date of this press release. Forward-looking
statements may involve known and unknown risks, uncertainties and
other factors that may cause the Company's actual results,
performance or achievements to be materially different from those
expressed or implied by the forward-looking statements, including
but not limited to statements regarding the opportunities and
prospects for our company, including our business, technologies and
products, the potential contributions of the new executives,
including the rebuilding of our commercial team, revenue
projections and market opportunity for products in our pipeline,
the development of our strategic and operating plans, our plan to
reduce expenses and our preliminary financial results. We do not
have revenue from product sales, and we may not be able to
successfully commercialize our pipeline products. These and other
risks are described more fully in our filings with the SEC,
including our quarterly report on Form 10-Q for the quarter ended
March 31, 2021 and other documents we
subsequently file with the SEC from time to time, including our
Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. Except to the extent required by
law, we undertake no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/zymergen-announces-executive-appointments-strengthening-leadership-team-in-key-areas-301349792.html
SOURCE Zymergen